CURR News and Press, Cure Pharmaceutical Holding Corp From 05/13/21

CURE Pharmaceutical (CURR) announces that it has secured International Organization for Standardization ((ISO)) 9001 certification for its Oxnard, California, manufacturing and research facility.The ISO tag is granted through a third party and confirms that CURE’s standard op...

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured International Organization for Standardization (ISO) 9001 certification for...

InStyle Magazine’s Editor in Chief and Host of Ladies First, Laura Brown Moderated the Intimate Conversation Sera Labs , a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), headlined Collision 2021 and discussed the changing landscape of beauty,...

CURE Pharmaceutical (CURR) announces successful results from initial clinical trials for erectile dysfunction product CUREfilm Blue.CUREfilm Blue utilizes the company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm, to deliver the active pharmaceuti...

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated specialty pharmaceutical company, announced today successful results from its initial Pharmacokinetics (PK)/bioequivalence studies. CURE will ...

CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that Rob Davidson, CURE’s Chief Executive Officer, and Nancy Duitch, CEO of subsidiary Sera Labs and Chief Strategic Officer of CURE, will be ...

Kidman and Duitch to discuss how cutting-edge delivery system technology will revolutionize the beauty industry Sera Labs , a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today that Academy Award, Golden Globe and Emmy Award-winning actor/pr...

CURE Pharmaceutical Holding Corp. (CURR): FY Gross profit of ~$1.0MRevenue of $2.1M (+ 229.0% Y/Y)Press Release For further details see: CURE Pharmaceutical Holding Corp. reports FY results

Fiscal Year 2020 Highlights: Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary The Se...

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured an extension to its Schedule I U.S. Drug Enforcement Agency (DEA) license that ...